Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MediBeacon Transdermal GFR Pivotal Study
NCT05425719Phase 3Completed
- Sponsor
- MediBeacon
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of relmapirazin in chronic kidney disease (CKD) (2 arms), sponsored by MediBeacon. Primary endpoint: Proportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate at 24 hours. Started Jun 2022; status: completed.
02
Drugs
relmapirazin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05425719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425719.